XSTOGETI B
Market cap4.30bUSD
Dec 20, Last price
174.05SEK
1D
0.37%
1Q
-22.68%
Jan 2017
20.87%
Name
Getinge
Chart & Performance
Profile
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, logistic automation solutions, bioreactors, bioprocess control systems, bioprocess software, biobundles, bioprocess analytics, and perfusion systems; practice-oriented monitoring systems and disposables, anesthesia machines, beating heart stabilizers and positioners, axius blower mister and coronary shunts, proximal seal systems, ceiling supply units, connected solutions, cleaning and disinfection products, packaging and sealing solutions, monitors and indicators, and SteriTec products. The company also provides thoracic catheters, dry seal chest drain, mobile dry seal drain, dry and wet suction water seal chest drain, and chest drain valves; transitional accessories; endoscope reprocessing; endoscopic vessel harvesting systems; endovascular products; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packing products; intra-aortic balloon counter pulsation therapies; mechanical ventilation products; medical furniture; modular room systems; operating lights and tables; OR integration and management; patient flow management; patient transport; sterile supply management; sterilization; surgical assist systems; surgical perfusion; transport & storage; trays & baskets; and vascular and cardiothoracic surgery solutions. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 31,827,000 12.50% | 28,291,000 4.59% | 27,049,000 -9.29% | |||||||
Cost of revenue | 27,998,000 | 24,453,000 | 22,247,000 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 3,829,000 | 3,838,000 | 4,802,000 | |||||||
NOPBT Margin | 12.03% | 13.57% | 17.75% | |||||||
Operating Taxes | 915,000 | 956,000 | 1,187,000 | |||||||
Tax Rate | 23.90% | 24.91% | 24.72% | |||||||
NOPAT | 2,914,000 | 2,882,000 | 3,615,000 | |||||||
Net income | 2,412,000 -3.17% | 2,491,000 -16.13% | 2,970,000 -8.31% | |||||||
Dividends | (1,158,000) | (1,090,000) | (817,000) | |||||||
Dividend yield | 1.90% | 1.85% | 0.76% | |||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 3,116,000 | 793,000 | 811,000 | |||||||
Long-term debt | 6,439,000 | 6,345,000 | 4,531,000 | |||||||
Deferred revenue | 1,513,000 | 4,252,000 | ||||||||
Other long-term liabilities | 4,870,000 | 3,405,000 | 125,000 | |||||||
Net debt | 6,766,000 | 1,412,000 | 1,214,000 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 2,957,000 | 3,367,000 | 6,560,000 | |||||||
CAPEX | (1,353,000) | (1,136,000) | (930,000) | |||||||
Cash from investing activities | (6,543,000) | (1,470,000) | (1,329,000) | |||||||
Cash from financing activities | 511,000 | (500,000) | (7,237,000) | |||||||
FCF | 567,000 | 1,100,000 | 6,377,000 | |||||||
Balance | ||||||||||
Cash | 2,728,000 | 5,676,000 | 4,076,000 | |||||||
Long term investments | 61,000 | 50,000 | 52,000 | |||||||
Excess cash | 1,197,650 | 4,311,450 | 2,775,550 | |||||||
Stockholders' equity | 23,614,000 | 23,664,000 | 18,388,000 | |||||||
Invested Capital | 40,638,350 | 34,928,550 | 30,550,450 | |||||||
ROIC | 7.71% | 8.80% | 11.57% | |||||||
ROCE | 8.80% | 9.50% | 14.03% | |||||||
EV | ||||||||||
Common stock shares outstanding | 272,370 | 272,370 | 272,370 | |||||||
Price | 224.30 3.70% | 216.30 -45.25% | 395.10 105.67% | |||||||
Market cap | 61,092,495 3.70% | 58,913,539 -45.25% | 107,613,218 105.67% | |||||||
EV | 68,095,495 | 60,740,539 | 109,254,218 | |||||||
EBITDA | 5,922,000 | 5,865,000 | 6,616,000 | |||||||
EV/EBITDA | 11.50 | 10.36 | 16.51 | |||||||
Interest | 493,000 | 205,000 | 152,000 | |||||||
Interest/NOPBT | 12.88% | 5.34% | 3.17% |